作者:Masaharu Iwakawa、Olivier R. Martin、Walter A. Szarek
DOI:10.1016/0008-6215(83)84009-9
日期:1983.9
-isopropylidene-3- O - p -tolylsulfonyl-α- d - ribo -hex-5-enofuranose and reduction of the resulting iodide(s). In the second approach, 5-deoxy-1,2- O -isopropylidene-3- O - p -tolylsulfonyl-β- d - xylo -hexofuranose was acetolyzed and condensed with 4-acetyl- N -bis(trimethylsilyl)cytosine, and alkaline treatment gave 11 by way of a 2′,3′-anhydro intermediate. The structure of 11 , in particular the configuration
摘要1-(5-脱氧-β-d-阿拉伯糖-呋喃糖基)胞嘧啶(4'-homoara-C)(11)是抗白血病药物ara-C(1-β-d-阿拉伯呋喃糖基胞嘧啶)的较高同源物。由两条独立的路线准备。第一个涉及通过碳酸二苯酯技术反转d-核糖差向异构体(1-(5-脱氧-β-d-核糖-六呋喃糖基)胞嘧啶,4'-高胞苷)的C-2'构型;通过将三氟乙酸碘抗马氏化学加成到5,6-二-脱氧-1,2-O-异亚丙基-的双键上,获得4'-高胞嘧啶的5-deoxy-d-d-核糖-呋喃糖基部分。 3-O-对甲苯磺酰基-α-d-核糖-hex-5-烯呋喃糖和减少的碘化物。在第二种方法中,5-deoxy-1 将2-O-异亚丙基-3-O-对甲苯磺酰基-β-d-二甲苯基-六呋喃糖乙酰化并与4-乙酰基-N-双(三甲基甲硅烷基)胞嘧啶缩合,然后通过2'进行碱处理,得到11 3'-脱水中间体。11的结构,特别是在C-2'处的构型,由其1 H-和13